Freeport-McMoRan heads into the final day of April carrying a wound that is hard to ignore — a 19% drop over the week to $56.93, capped by a further 2.2% fall on Wednesday, and all of it arriving in the same week the company disclosed a Grasberg production slump.
The Q1 earnings print on April 23 set the tone. The stock shed 13.2% that day alone — the largest single-session reaction in the recent history on record. The miss came against a backdrop of already elevated macro anxiety around copper, and the Grasberg production slump headline amplified the damage through the rest of the week. The next earnings event is pencilled in for June 10. That is now the nearest hard catalyst on the calendar.
The positioning picture does not show an aggressive short-building response to any of this. Short interest has nudged higher over the week — up about 2.2% to roughly 1.94% of the free float — but that is a very small absolute position for a stock this size, and the 30-day change is just 0.4%. Availability in the lending market remains extremely loose: the lending pool is barely 1% utilised, down from a 52-week peak of 4.8%, meaning there is virtually unlimited room for new shorts if sentiment were to turn meaningfully more negative. Cost to borrow has drifted higher — up 25% over the week to 0.35% — but that is still a trivially cheap rate; this is not a stock where borrow pressure is creating squeeze dynamics. Options are equally calm. The put/call ratio is running at 1.0047, fractionally below its 20-day average of 1.01 and well within one standard deviation of normal. For a stock that just dropped 19% in a week, the derivatives market is notably unbothered.
The Street is more conflicted. Morgan Stanley delivered the sharpest signal: on April 24, the day after the earnings selloff, it downgraded FCX to Equal-Weight from Overweight and cut its target from $70 to $66 — a meaningful pivot from a bellwether firm. The move contrasts with UBS, which on April 29 raised its target to $74 (from $66 earlier in April), and Wells Fargo, which maintained Overweight and lifted to $77 on April 15. JPMorgan stayed Overweight with a $76 target earlier in the month. Goldman Sachs initiated at Buy in early April with a $70 target. The consensus mean sits at $67.90, implying roughly 19% upside from current levels — but that figure was pulled down by the Morgan Stanley cut and still carries targets set before the full extent of the Grasberg news was absorbed. The bull case rests on long-life assets, Grasberg licence extension accretion, and a structural copper deficit. The bear case is exactly what just played out: a mud rush incident and infrastructure damage at Grasberg, delayed production restart, and lower EBITDA guidance. EV/EBITDA is running at 7.65x, up modestly over the past month as earnings estimates have been revised down faster than the stock fell initially. The P/E has expanded to 19.6x on the same dynamic. EPS momentum over 30 days ranks in the bottom 12th percentile — forward estimates are moving the wrong way.
Institutional ownership is dense and passive-heavy. Vanguard holds 9.1% of shares, BlackRock 7.5%, and State Street 4.4%. Putnam notably added 2 million shares in the quarter to March 31. Insider activity is dated — the most recent trades cluster around February 13, when the CFO, Chairman, and several other executives sold shares at prices between $62 and $65. Those sales look prescient in hindsight but are too old to read as a current signal. The net 90-day insider position is a modest net sale of approximately $53 million in value, spread across multiple officers — routine rather than alarming.
Peers confirm that this week's pain was sector-wide. SCCO fell 10.3% and First Quantum (FM) lost 15.2%, suggesting macro copper pressure and not just Grasberg idiosyncrasy drove part of the move. FCX's 19% decline was the worst of the peer set, which indicates the production news did add stock-specific damage on top of the sector drawdown.
What to watch from here: whether the Street's target revisions stabilise or continue lower as the June 10 earnings date approaches, and whether the Grasberg production timeline gets more clarity in interim company communications — the gap between the bulls holding $74-$77 targets and the Morgan Stanley move to the sidelines is the central tension in the name right now.
See the live data behind this article on ORTEX.
Open FCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
